

1 **Title: “How does acute pain influence biomechanics and quadriceps function in**
2 **individuals with patellofemoral pain?”**

3
4
5
6 ***Corresponding author:***

7 Dr. Henrike Greuel,

8 School of Health Science, University of Salford, UK

9 Frederick road campus, Brian Blatchford building, PO30, Salford M66PU, Greater
10 Manchester,

11 H.Greuel@edu.salford.ac.uk, 44 (0) 161 2952017

12
13 ***Co-authors:***

14 Dr. Lee Herrington, l.c.herrington@salford.ac.uk, School of Health Science, University of
15 Salford, Salford, UK

16 Dr. Anmin Liu, a.liu@salford.ac.uk, School of Health Science, University of Salford,
17 Salford, UK

18 Prof. Richard K. Jones, r.k.jones@salford.ac.uk, School of Health Science, University of
19 Salford, Salford, UK

20
21
22
23 ***Word count:*** 3193 words manuscript

24 ***Word count abstract:*** 228

25
26 ***number of tables:*** 4

27 ***Number of figures:*** 1

28 ***number of references:*** 33

29
30 ***Key words:*** patellofemoral pain, knee, PFP, AKP, inhibition, quadriceps, strength, pain

31

32

33 **Abstract**

34 **Objectives:**

35 Beside pathophysiological factors, pain is believed to play a crucial role in the progression of
36 patellofemoral pain (PFP). However, the isolated effect of pain on biomechanics and
37 quadriceps function has not been investigated in PFP. Thus, this study aimed to investigate the
38 effect of pain on quadriceps function and lower limb biomechanics in individuals with PFP.

39 **Methods**

40 Twenty-one individuals with PFP (11 males and 10 females, age: 29.76 ± 6.36 years, height:
41 1.74 ± 0.09 m, mass: 70.12 ± 8.56 kg) were measured at two different occasions: when not and
42 when experiencing acute pain. Peak quadriceps torque (concentric, eccentric and isometric)
43 and arthrogenic muscle inhibition (AMI) was assessed. Three-dimensional motion analysis and
44 surface electromyography of the quadriceps and hamstrings muscles were collected during
45 running, a single-leg-squat and step-down task. The normality was assessed using the Shapiro-
46 Wilk test and a MANOVA was performed at the 95% confidence interval.

47 **Results**

48 AMI increased significantly in acute pain. The net muscle activation of the knee extensors and
49 flexors decreased during running in acute pain. The lower limb biomechanics and the
50 quadriceps torque did not change in acute pain.

51 **Discussion:**

52 It appears that even if individuals with PFP experience pain they can still deliver maximal
53 quadriceps contractions and maintain their moving patterns without biomechanical changes.
54 However, the overall reduced activation of the quadriceps and the increased AMI indicate the
55 presence of quadriceps inhibition in acute pain.

56 **Key words:** patellofemoral pain, knee, PFP, AKP, inhibition, quadriceps, strength, pain

57 **1. Introduction**

58 Patellofemoral pain (PFP) is commonly diagnosed in individuals with knee injuries and often
59 affects younger and active populations [1]. Follow-up studies showed that the majority of
60 individuals with PFP still suffered from pain and dysfunction, despite initially received
61 treatment and education; Lankhorst et al. reported an unfavourable recovery at 5 to 8 years of
62 57% of individuals with PFP [2] and Stathopulu & Baildam found that 91% of patients still
63 suffered from PFP 4-18 years after their initial presentation at a hospital [3]. Thus, the long-
64 term prognosis of PFP is still poor, which raises the question whether the pathophysiological
65 factors that cause PFP are understood and addressed in treatments sufficiently. Currently,
66 pathophysiological factors associated with PFP can be compared with a complex mosaic where
67 various anatomical, biomechanical, psychological and social factors are interconnected to each
68 other and are likely to contribute to pain [4]. Long-term studies showed that individuals with
69 PFP with greater durations of pain and worse pain were more likely to develop an unfavourable
70 outcome and a more progressive pathology [5, 6]. Thus, it is believed that pain might play a
71 role in the aetiology and progression of PFP [7].

72 Previous studies have reported a link between PFP and lower limb muscle weakness and
73 inhibition, knee instability, and functional performance [8-10]. However, all studies either
74 correlated the pain intensity to specific factors or based their findings on the comparison of the
75 pain intensity before and after a treatment. The only studies that investigated the direct
76 influence of acute knee pain on muscular function and lower limb biomechanics analysed the
77 effect of artificially induced knee pain [11-14]. These studies demonstrate a link of pain to
78 several factors, such as alterations of lower limb biomechanics, muscular coordination,
79 quadriceps strength and arthrogenic muscle inhibition (AMI). AMI describes an ongoing reflex
80 response which results in an inability to completely contract a muscle voluntarily, despite no
81 structural damage to the muscle or innervating nerve [15, 16]. AMI is closely linked to knee
82 pain, because it is caused by altered afferent input originating from mechanoreceptors and
83 nociceptors, which reflexively reduce the efferent quadriceps alpha motor-neuron output [16,
84 17]. However, the isolated effect of pain in individuals with PFP has not been investigated.

85 Individuals with PFP commonly show altered movement patterns and aberrant muscle function
86 [4], but it remains unclear whether these changes are consequence of pain or are causal factors
87 in the development of PFP. It also remains unknown to what extent acute pain would influence
88 the functional performance and muscular function in individuals with PFP. A better

89 understanding of the influence of pain in individuals with PFP would provide further insights
90 into PFP that might help to optimise management and treatment of PFP. Therefore, this study
91 aimed to investigate the direct effect of acute PFP on quadriceps strength and AMI, quadriceps
92 and hamstrings co-contraction and hip and knee biomechanics.

93

94 **2. Methods**

95 The study was approved by the University of Salford Research and Governance Committee
96 (HSR 15-143) and the trial was registered at ClinicalTrials.gov (NCT02914574). The informed
97 consent was obtained from each participant. Posters and flyers at fitness centres, gyms, and
98 sports clubs in Manchester and Salford were used to recruit participants with PFP and without
99 PFP.

100

101 **2.1. Participants**

102 The inclusion and exclusion criteria, as well as the clinical assessment were developed based
103 on current recommendations [18]. The inclusion criteria for participants with PFP were: (1)
104 aged 18-45 years (to exclude patients with knee or patellar osteoarthritis); (2) antero- or retro-
105 patellar pain with at least two of these activities: ascending or descending stairs or ramps,
106 squatting, kneeling, prolonged sitting, hopping/ jumping, isometric quadriceps contraction or
107 running (3) duration of current PFP symptoms >1 month

108 The exclusion criteria were: (1) any history of previous lower limb surgery or patella instability
109 and dislocation, (2) lower limb deformities or any history of traumatic, inflammatory or
110 infectious pathology in the lower extremities or any internal derangements, (3) not able to
111 perform running, squatting and the step-down task during the measurement. (4) Those who
112 failed to satisfy the above listed inclusion criteria.

113 Since there is no definite clinical test to diagnose PFP, further clinical assessment were carried
114 out, which involved the Clarke's test, a palpation test of the patellar edges and a single leg
115 squat task to investigate the pain region [18]. These three tests have been chosen based on the
116 current recommendations and have shown to provide limited to good diagnostic evidence [18].
117 All clinical assessments were performed by the same experienced musculoskeletal

118 physiotherapist. All participants were fitted with standard running shoes (New Balance, model
119 M639SA UK), to control the interface of the shoe and the surface.

120 The participants were asked to attend the first appointment whilst not experiencing pain and
121 the second appointment whilst experiencing acute pain. This order was set to ensure, that the
122 participants had time to raise questions and concerns during the first visit, before they
123 performed the exercises that triggered their acute PFP. Both measurement sessions were
124 scheduled within one week. The participants were instructed to perform exercises before the
125 second appointment which they were familiar with and were sure would trigger their acute
126 PFP. Since the participants performed the exercises independently between the first and second
127 assessment, the researchers were unable to control the exercises. However, the researcher
128 documented the form of exercises the participants had chosen; Twelve participants chose
129 running and 9 participants chose eccentric quadriceps exercises (in particular lunges and
130 squats) to trigger the acute PFP. The pain intensity was reported but participants were not
131 instructed to self-inflict their acute pain up to a specific pain intensity level. Instead the
132 participants were instructed to self-inflict the pain to the extent that they experienced as their
133 familiar acute PFP. To ensure that they were not fatigued they were asked to not perform the
134 painful activity at least 5 hours before coming to the second appointment and were advised to
135 rest before arriving at the gait laboratory.

136

137 **2.2. 3D movement analysis**

138 Three-dimensional motion data were collected with ten Qualisys OQUS7 cameras (Qualisys
139 AB, Sweden) at a sampling rate of 250Hz. Three force plates (BP600900, Advanced
140 Mechanical Technology, Inc. USA) were used to collect the force data at a sampling rate of
141 1500Hz. The calibrated anatomical system technique (CAST) model, which included
142 anatomical landmarks (markers on anatomical bony landmarks) and anatomical frames
143 (segment mounted marker clusters), was used in the biomechanical modelling and analysis
144 [19]. Retroflective markers were placed, with double sided hypoallergic tape to the following
145 anatomical landmarks of both lower limbs of the participant: the anterior superior iliac spine
146 (ASIS), the posterior superior iliac spine (PSIS), the iliac crest, the greater trochanter, the
147 medial and lateral femoral epicondyle, the medial and lateral malleoli, the posterior calcanei,
148 and the head of the first, second and fifth metatarsals. The anatomical frames were rigid clusters

149 of 4 nonorthogonal markers and were positioned over the lateral shank, and the lateral thigh of
150 the limbs (Figure 1) [19].

151 For the electrode placement of the surface Electromyography (sEMG), the skin was shaved,
152 abraded and cleaned with isopropyl alcohol. The sEMG electrodes (Noraxon Dual Electrodes,
153 2cm spacing) were placed on the vastus medialis, vastus lateralis, biceps femoris and
154 semitendinosus muscle in accordance with the SENIAM guidelines [20]. The sEMG data were
155 collected with the Noraxon Telemetry system at a sampling rate of 1500Hz. The sEMG data
156 were synchronised to the kinematic and kinetic data.

157 All participants were measured at one occasion without acute pain or only very light pain and
158 at the second occasion while the participant experienced acute pain. The participants were
159 asked on both occasions to rate their pain intensity using the numeric pain rating scale (NPRS)
160 after performing the biomechanical tasks. To investigate whether the application of the 3D
161 markers and bandages modified the pain, each participant was asked to rank his/her pain
162 intensity with and without the applied bandages and markers. Each subject was asked at both
163 occasions to perform a static trial and to run on a 15m walkway at a self-selected speed.
164 Running speed was measured and reported by using Brower timing lights (Draper, UT). The
165 participant was asked to perform a single leg squat and a step-down test while holding his/her
166 arms folded across his/her chest. Both tasks were demonstrated and explained by the
167 researcher. Each task was performed until five successful trials were collected. Unsuccessful
168 trials were ones whereby less than three markers per segment were visible or a partial/double
169 foot contact with one of the force platforms happened.



170

171 **Figure 1: The placement of the markers and the sEMG electrodes**

172

173 **2.3. Quadriceps strength and inhibition analysis**

174 At both occasions each subject was asked to perform three times the following knee extensor
175 strength tests: an isometric, an eccentric and a concentric test. The peak torque was measured
176 with an isokinetic dynamometer (Kin-Com, Chattanooga, USA). Participants were positioned
177 in 90° hip flexion and 60° knee flexion in an isokinetic dynamometer and secured to the test
178 chair with a chest and pelvic belt. The Kin-Com shin pad was attached 1 cm proximal to the
179 malleoli of the ankle (Figure 2). The isokinetic knee extensor torque measurements were tested
180 at the angular velocity of 60 degrees/second. The participants were advised to keep their arms
181 across their chest.

182 The muscular inhibition of the quadriceps was assessed, during a maximal voluntary isometric
183 contraction (MVIC) of the quadriceps with the interpolated twitch technique, using a single
184 twitch with a pulse duration of 200 ms and a stimulus amplitude of 125mA (DS7AH Digitimer
185 Ltd, Hertfordshire, England). Two electrodes (proximal: 50×130 mm, distal: 7.5×100 mm)
186 (Axelgaard, Fallbrook, Ca, USA) were placed on the quadriceps muscle at one-third and two-

187 thirds from the distance between the anterior superior iliac spine and the upper border of the
188 patella [21].

189 Prior to the test a warm-up session of 4 submaximal isometric and isokinetic quadriceps
190 contractions were performed. The submaximal testing at around 50% of the participants MVIC
191 was chosen to ensure that the participant was warmed up and familiarised with the
192 measurement without feeling fatigued. After the warm-up a familiarisation of the stimulation
193 sensation was made with several test stimuli. Prior to the isometric MVIC two single twitches
194 of 125 mA were triggered by the assessor on the relaxed quadriceps. During the MVIC attempt
195 two single pulses of 200 μ s duration, 200Volt and 125 mA were triggered by the investigator
196 when the MVIC force had plateaued on the monitor. The strength data and AMI data of each
197 participant was exported from the Kin-Com to ascii-files and loaded into Excel. The peak
198 concentric, eccentric and isometric torque was determined for each file. AMI was quantified
199 by calculating the difference between the stimulus-evoked torque during MVIC (ITT in Nm)
200 to the stimulus-evoked torque at rest (RTT in Nm) and expressed in %: activation deficit (AD)
201 at 100% MVIC from the ratio: $AD = (ITT/RTT) \times 100$. An inhibition of 0% means that the
202 subject was able to fully recruit the muscle without showing any signs of inhibition.



203

204 **Figure 2: Knee extensor strength and quadriceps arthrogenic muscle inhibition measurement**

205

206 **2.4. Processing of 3D motion data**

207 The kinematic and kinetic outcomes were calculated using a 6 degrees of freedom model in
208 Visual3D (Version 5, C-motion Inc., USA). The pelvis, thigh, shank, foot and virtual foot
209 segments were defined and 4 tracking markers were used for each segment. Ankle and knee
210 joint centers were calculated as midpoints between the malleoli and femoral epicondyles
211 respectively and the hip joint center was calculated using the regression model of Bell et al.
212 [22] based on the ASIS and PSIS markers. The global coordinate system was defined as x for
213 the forward/ backward, z the vertical and y the left/ right (medial/ lateral) axis. Marker motion
214 data and the analogue data from the force plate were filtered with a 4th order lowpass
215 Butterworth filter with cut-off frequencies of 12Hz. The joint moments were calculated using
216 three dimensional inverse dynamics and normalised to body mass. The kinematic and kinetic
217 data were normalised to 100% of a single leg squat, a step-down task and the stance phase in
218 running, whereby the stance phase was sub-grouped in early (0-24% of stance phase), mid (25-
219 62%) and late-stance phase (63%-100%) [23]. The peaks of the hip and knee flexion, adduction
220 and internal rotation angles and the moments were calculated for the single leg squat, step-
221 down task and the early, mid and late-stance phase. Furthermore, the average knee angular
222 velocity was calculated for the eccentric phase during the single leg squat and step-down task.
223

224 **2.5. Processing of sEMG data**

225 The sEMG data was band-pass filtered at 20-500 Hz and rectified by using a root mean square
226 over a 75 ms window for the running task and 300 ms for the single leg squat and step-down
227 task [24]. Co-contraction ratios were (CCR) calculated by using the formula of Heiden et al.:

228 If agonist mean EMG > antagonistic mean EMG:

$$229 \quad \text{CCR} = 1 - \frac{\text{antagonistic mean EMG}}{\text{agonist mean EMG}}$$

230 If agonist mean EMG < antagonistic mean EMG:

$$231 \quad \text{CCR} = \frac{\text{agonist mean EMG}}{\text{antagonistic mean EMG}} - 1 \text{ [25]}$$

232 The peak quadriceps torque was determined for each file and AMI was calculated during the
233 isometric contraction.

234

235 **2.6. Statistical analysis**

236 The statistical analysis was performed using SPSS (v. 20, IBM, USA) and Excel 2013
237 (Microsoft, USA). The normality was assessed by applying the Shapiro-Wilk test and by the
238 investigation of the normal q-q plots. The Wilcoxon rank test was used with a significance
239 level set at $p < 0.05$ to investigate the ordinal data (pain scale).

240 Kinematic and kinetic variables, quadriceps strength, quadriceps AMI and co-contraction ratios
241 were compared between the two conditions: with and without acute pain using a one way
242 repeated measures MANOVA. The standard error of mean (SEM) was calculated using the
243 following formula: $SEM = SD/\sqrt{\text{sample size}}$. The effect size for each variable was calculated
244 using the Cohen d to give an indication of the magnitude of the effect of acute pain (>0.8
245 large effect, 0.5 moderate effect, <0.3 small effect) [26].

246

247 **3. Results**

248 Twenty-one individuals with PFP (11 males and 10 females, age: 29.76 ± 6.36 years, height:
249 $1.74 \pm 0.09\text{m}$, mass: $70.12 \pm 8.56\text{kg}$) participated in the study. The running speed without and
250 with pain was not significantly different ($p=0.608$) (without pain: $3.32 \pm 0.71\text{m/s}$, with pain: 3.4
251 $\pm 0.15\text{m/s}$).

252 The application of the bandage and the markers did not result in significant changes in pain
253 under both test conditions (NPRS: baseline pain: without marker application: 1.29 ± 1.95 ; with
254 application: 1.17 ± 1.95 , $p=0.582$, acute pain: without application: 3.88 ± 1.92 ; with application:
255 3.86 ± 1.96 , $p=0.902$). Pain was significantly increased when participants performed the tasks
256 with acute pain (with and without pain: $p=0.0001$). A clinically significant change in pain has
257 been described as 1.74 points, thus the pain increase by 2.59 represents a clinical meaningful
258 increase in pain [27].

259 Only during the late-stance phase in running the external knee flexion moment significantly
260 decreased with a moderate effect size in acute pain ($p=0.042$) (Table 2). Although the change
261 was not significant a moderate effect size indicated also a reduction of the external knee flexion
262 moment during the mid-stance phase.

263 The net activation of the knee extensors and flexors decreased significantly during the early
264 and mid-stance phase with medium to large effect sizes (quadriceps: 32.2% reduction, $p=0.025$,
265 hamstrings: 11.4% reduction, $p=0.008$) in acute pain (Table 3).

266 The peak isometric, concentric and eccentric torque did not change with or without acute pain
267 (Table 4). However, the AMI increased significantly in acute pain with a moderate effect size
268 (6.56% increase, $p=0.035$) (Table 4).

269 **Table 1: The lower extremity kinematics during the single leg squat task and the step-down task with and**
 270 **without acute pain (*indicated the results were significantly different.)**

The kinematic variables (°) during the single leg squat and step-down task		Without pain			With acute pain			P value: (T-test, sig 2- tailed)	Effect size
		Mean	SD	Std. Error Mean	Mean	SD	Std. Error Mean		
Single leg squat	Hip flexion angle	75.7	15.6	3.4	76.9	16.4	3.6	0.813	0.08
	Hip adduction angle	14.5	7	1.5	13.6	7.6	1.7	0.697	0.08
	Hip internal rotation angle	1.9	7.5	1.6	0.7	7.8	1.7	0.607	0.16
	Knee flexion angle	81.1	9.3	2	81.9	10.7	2.3	0.786	0.08
	Knee adduction angle	5.3	4.7	1	4.2	4.5	1	0.460	0.24
	Knee internal rotation angle	-2.5	6.3	1.4	-1.5	5.9	1.3	0.575	0.16
Step- down task	Hip flexion angle	71.8	18.2	4	74.5	15	3.3	0.608	0.16
	Hip adduction angle	16.4	6.7	1.5	15.7	6.7	1.5	0.717	0.10
	Hip internal rotation angle	2.2	6.8	1.5	0.6	7.6	1.7	0.485	0.22
	Knee flexion angle	89.4	14	3.1	90.3	13	2.8	0.842	0.07
	Knee adduction angle	5.4	4.4	1	4.5	4.6	1	0.508	0.2
	Knee internal rotation angle	-1.1	6.5	1.4	-1.1	6.1	1.3	0.977	0
Early- stance phase	Hip flexion angle	36.5	5.9	1.3	36.8	5.5	1.2	0.835	0.05
	Hip adduction angle	7.1	4.6	1	6.7	4.8	1.1	0.746	0.09
	Hip internal rotation angle	2.9	7.9	1.7	3.4	7.4	1.6	0.895	0.07
	Knee flexion angle	30.6	3.9	0.9	31.6	4	0.9	0.460	0.25
	Knee adduction angle	2.2	3.4	0.7	2.5	3.9	0.8	0.779	0.08
	Knee internal rotation angle	-4.8	5.9	1.3	-3.9	5.2	1.1	0.373	0.18
Mid- stance phase	Hip flexion angle	34.6	6.5	1.4	34.9	5.9	1.3	0.946	0.05
	Hip adduction angle	11.5	4.8	1	10.1	5.3	1.2	0.387	0.28
	Hip internal rotation angle	-0.1	7.5	1.6	-0.9	8.7	1.9	0.908	0.10
	Knee flexion angle	43.3	5	1.1	44.6	5	1.1	0.824	0.26
	Knee adduction angle	1.7	3.3	0.7	0.9	4.8	1	0.784	0.19
	Knee internal rotation angle	1	6.3	1.4	1.2	5.5	1.2	0.783	0.03
Late- stance phase	Hip flexion angle	21.1	5.7	1.2	21	5.2	1.1	0.856	0.18
	Hip adduction angle	7.2	5	1.1	7	4.9	1.1	0.279	0.04
	Hip internal rotation angle	1.1	7.4	1.6	0.2	9.2	2	0.594	0.11
	Knee flexion angle	40.9	4	0.9	41.7	4.6	1	0.441	0.19
	Knee adduction angle	1.2	2.7	0.6	1.1	3.8	0.8	0.514	0.03
	Knee internal rotation angle	0	7.1	1.5	0.6	5.4	1.2	0.651	0.10

272 **Table 2: The lower extremity kinetics during the single leg squat task and the step-down task with and**
 273 **without acute pain (*indicated the results were significantly different.)**

The kinetic variables (Nm/kg) during the single leg squat and step-down task		Without pain			With acute pain			P value: (T-test, sig 2-tailed)	Effect size
		Mean	SD	Std. Error Mean	Mean	SD	Std. Error Mean		
Single leg squat	Hip flexion moment	1.29	0.55	0.12	1.34	0.55	0.12	0.790	0.09
	Hip adduction moment	0.95	0.28	0.06	0.91	0.2	0.04	0.636	0.16
	Hip internal rotation moment	-0.14	0.05	0.01	-0.15	0.07	0.02	0.619	0.16
	Knee flexion moment	1.74	0.41	0.09	1.67	0.28	0.06	0.556	0.20
	Knee adduction moment	0.33	0.12	0.03	0.3	0.11	0.02	0.421	0.26
	Knee internal rotation moment	0.4	0.09	0.02	0.37	0.09	0.02	0.350	0.33
Step-down task	Hip flexion moment	1.49	0.72	0.16	1.58	0.69	0.15	0.690	0.13
	Hip adduction moment	1.13	0.27	0.06	1.06	0.2	0.04	0.387	0.29
	Hip internal rotation moment	-0.1	0.07	0.02	-0.12	0.06	0.01	0.405	0.31
	Knee flexion moment	1.74	0.35	0.08	1.69	0.29	0.06	0.594	0.16
	Knee adduction moment	0.39	0.18	0.04	0.35	0.14	0.03	0.475	0.25
	Knee internal rotation moment	0.4	0.09	0.02	0.37	0.09	0.02	0.252	0.33
Early-stance phase	Hip flexion moment	2.03	0.42	0.09	1.99	0.4	0.09	0.545	0.10
	Hip adduction moment	1.24	0.45	0.1	1.08	0.33	0.07	0.396	0.41
	Hip internal rotation moment	0.05	0.12	0.03	0.06	0.09	0.02	0.946	0.09
	Knee flexion moment	1.42	0.48	0.11	1.38	0.33	0.07	0.060	0.10
	Knee adduction moment	0.52	0.28	0.06	0.45	0.26	0.06	0.576	0.26
	Knee internal rotation moment	0.22	0.1	0.02	0.2	0.11	0.02	0.648	0.19
Mid-stance phase	Hip flexion moment	0.94	0.59	0.13	0.87	0.42	0.09	0.986	0.14
	Hip adduction moment	1.95	0.42	0.09	1.82	0.47	0.1	0.710	0.29
	Hip internal rotation moment	-0.26	0.17	0.04	-0.26	0.17	0.04	0.523	0
	Knee flexion moment	2.89	0.72	0.16	2.48	0.77	0.17	0.078	0.55
	Knee adduction moment	0.55	0.29	0.06	0.5	0.3	0.07	0.918	0.17
	Knee internal rotation moment	0.44	0.14	0.03	0.41	0.15	0.03	0.764	0.21
Late-stance phase	Hip flexion moment	-0.03	0.28	0.06	0.02	0.26	0.06	0.540	0.19
	Hip adduction moment	1.43	0.42	0.09	1.37	0.46	0.1	0.680	0.14
	Hip internal rotation moment	0.02	0.03	0.01	0.02	0.04	0.01	0.778	0
	Knee flexion moment	1.96	0.51	0.11	1.68	0.51	0.11	0.042*	0.55
	Knee adduction moment	0.36	0.21	0.05	0.33	0.21	0.05	0.742	0.14
	Knee internal rotation moment	0.25	0.11	0.02	0.23	0.11	0.02	0.600	0.19

275 **Table 3: Co-contraction ratio, net activation of the knee flexors and knee extensors during the stance phase**
 276 **in running, the single leg squat task and the step-down task with and without acute pain, (*indicated the**
 277 **results were significantly different.)**

		Without pain			With acute pain			P value: (T-test, sig 2- tailed)	Effect size
		Mean	SD	Std. Error Mean	Mean	SD	Std. Error Mean		
Single leg squat	Co-contraction ratio (knee ext: knee flx.)	0.6	0.28	0.07	0.65	0.19	0.05	0.331	0.20
	Net activation knee extensors in %	74.97	36.65	8.64	52.95	35.32	8.32	0.177	0.61
	Net activation knee flexors in %	28.81	16.93	3.99	18.83	14.78	3.48	0.075	0.63
Step- down task	Co-contraction ratio (knee ext: knee flx.)	0.58	0.29	0.07	0.63	0.23	0.05	0.688	0.19
	Net activation knee extensors in %	72.43	30.6	7.21	52.81	36.72	8.66	0.283	0.58
	Net activation knee flexors in %	30.55	20.7	4.88	19.29	14.74	3.47	0.183	0.63
Early- stance phase	Co-contraction ratio (knee ext: knee flx.)	0.66	0.15	0.04	0.72	0.13	0.03	0.558	0.43
	Net activation knee extensors in %	134.49	67	15.79	102.29	59.11	13.93	0.025*	0.51
	Net activation knee flexors in %	38.26	17.91	4.22	26.86	17.99	4.24	0.008*	0.64
Mid- stance phase	Co-contraction ratio (knee ext: knee flx.)	0.32	0.24	0.06	0.41	0.25	0.06	0.882	0.37
	Net activation knee extensors in %	81.74	41.9	9.88	63.16	35.75	8.43	0.010*	0.48
	Net activation knee flexors in %	50.21	21.43	5.05	33.29	19.61	4.62	0.002*	0.82
Late- stance phase	Co-contraction ratio (knee ext: knee flx.)	-0.44	0.47	0.11	-0.33	0.44	0.1	0.117	0.24
	Net activation knee extensors in %	6.76	5.67	1.34	8.9	16.29	3.84	0.928	0.18
	Net activation knee flexors in %	20.03	15.55	3.67	14.05	10.98	2.59	0.096	0.44

278

279 **Table 4: Strength, AMI, time to peak, rate to force development and the break phenomenon with and**
 280 **without acute pain. (*indicated the results were significantly different.)**

	Without pain			With acute pain			P value: (T-test, sig 2- tailed)	Effect size
	Mean	SD	Std. Error Mean	Mean	SD	Std. Error Mean		
Isometric quadriceps strength (Nm/kg*100)	2.86	0.76	0.17	2.90	1.26	0.27	0.889	0.04
Eccentric quadriceps strength (Nm/kg*100)	3.14	1.40	0.30	2.74	0.69	0.15	0.249	0.36
Concentric quadriceps strength (Nm/kg*100)	1.74	0.71	0.15	1.88	0.57	0.12	0.480	0.22
AMI in %	10.58	9.33	2.04	17.14	12.71	2.77	0.035*	0.59

281

282 4. Discussion

283 To the authors' knowledge, this is the first study to investigate the direct influence of acute
 284 pain on hip and knee biomechanics, quadriceps and hamstrings activation and quadriceps
 285 strength and AMI in individuals with PFP. This study showed that despite acute pain, hip and
 286 knee kinematics were not significantly changed. However, the external knee flexion moment
 287 was slightly decreased in acute pain during the mid- and late-stance phase in running, which is
 288 in accordance with previous studies demonstrating that artificially induced knee pain resulted
 289 in a decreased knee flexion moment [11, 12]. A reduced knee flexion moment is believed to be
 290 caused by the quadriceps avoidance strategy, which is a compensatory strategy to decrease
 291 joint loading and thereby joint pain [28]. This assumption could be supported by the findings

292 of a significantly increased quadriceps inhibition, decreased quadriceps activation and the
293 slight decrease in the knee flexor moment. The simultaneously reduced activation of the
294 quadriceps and hamstrings muscles has been previously described in individuals with artificial
295 induced pain [12, 13].

296 A balanced co-contraction of the quadriceps and hamstrings activation might assist in knee
297 joint stabilisation in the frontal plane due to increased joint compression [29]. Thus, the overall
298 reduced co-contraction of the quadriceps and hamstrings muscles might result in knee
299 instability during the loading response and thus also might be responsible for the development
300 of pain and the greater reduction and variability of the knee flexion moment [12, 13]. However,
301 the reduced quadriceps muscle activation could also be a compensatory strategy to reduce
302 patellofemoral joint reaction forces during painful activities, which has been described in
303 literature as the quadriceps avoidance strategy.

304 The quadriceps avoidance strategy is believed to be often caused by quadriceps inhibition [12,
305 13, 30]. Rice et al. described that the inhibitory response of the quadriceps occurs partially due
306 to spinal reflex inhibition of the alpha-motor-neuron (MN) [31]. This reflex inhibition is
307 modulated by the pre- and postsynaptic mechanism and elicited by abnormal afferents from a
308 painful or damaged joint [21, 32]. Thereby the painful or damaged joint causes a decreased
309 motor drive to muscles and thus a limited muscle's potential to generate force [21]. Studies
310 which investigated the association of pain to AMI found that it was significantly associated to
311 knee pain [16, 21, 33] and that already 1 point increase on the visual analogue pain scale (VAS)
312 caused an increase in AMI of 1.6% [21]. These findings are in accordance with the results of
313 this study, where the pain increase of 1 on the NPRS caused an increase of 2.1% AMI. Thus,
314 AMI appears to play an important role in the injury cycle of knee pain.

315 Previous studies suggested an increase of the voluntary antagonist neural drive to overcome
316 any inhibitory contractions [30, 33]. In contrary, this study showed that pain caused a decrease
317 of the antagonistic muscles and thus indicates that not only the quadriceps, but also the
318 hamstrings muscles might be inhibited due to pain [14]. This suggests that pain suppressed the
319 motor output globally. But despite the significant altered muscle activation of the quadriceps
320 and the hamstrings muscle, no significant biomechanical changes or differences in the maximal
321 voluntary quadriceps contraction could be identified. Knee pain may be caused by a number of
322 structures, such as the infrapatellar fat pad with its nociceptive innervations [34]. Previous
323 studies have shown that knee pain, that was artificially induced in the quadriceps muscle or the

324 infrapatellar fat pad altered the coordination of the quadriceps muscle [12, 13, 35]. These
325 studies showed that pain caused a reduced activation and altered activation timing of the
326 quadriceps muscle, which is in accordance to our findings.

327 In contrary to our findings, previous studies have shown that pain also resulted in a decrease
328 of quadriceps strength [14, 33, 36]. However, these results were shown in healthy individuals
329 with artificially induced knee pain. Individuals with PFP experience knee pain frequently and
330 thus might show a different physical reaction to pain. Furthermore, in comparison to strength
331 results of individuals with PFP in previous studies the participants in this study appeared to
332 belong to a strong subgroup of individuals with PFP. Selfe et al. described three subgroups of
333 patients with PFP; a "strong subgroup" with high quadriceps and hip abductor strength scores,
334 a "weak and tight subgroup" with weak quadriceps and hip abductor muscles and low muscle
335 flexibility and a "weak and pronated foot subgroup" with weak quadriceps and hip abductor
336 muscles, greater patellar mobility and an increased foot pronation [37]. The strong subgroup
337 had quadriceps torque scores of 1.65 ± 0.53 Nm/kg in comparison with the weak groups with
338 quadriceps torque values of 0.84 ± 0.32 Nm/kg and 0.82 ± 0.32 Nm/kg. The group of individuals
339 with PFP who participated in this study were highly active and had an isometric quadriceps
340 strength score of: 2.86 ± 0.76 Nm/kg without acute pain and with acute pain of 2.9 ± 1.26
341 Nm/kg. These results demonstrate that participants with PFP that participated in this study were
342 stronger than previously reported in literature. The good training status of the participants with
343 PFP might have enabled them to deliver maximal quadriceps contractions and maintain their
344 moving patterns without biomechanical changes even when they experienced more pain and
345 had a presence of AMI. However, research on strong individuals with PFP is still lacking and
346 thus further research is needed to confirm these findings [37].

347

348 **2. Clinical implications**

349 These results indicate that quadriceps AMI appears to be a crucial factor in acute PFP. AMI is
350 present in a wide range of knee joint pathologies and described as a reflexive "shut-down" of
351 the quadriceps muscle [16]. Immediately after knee injuries a decreased voluntary quadriceps
352 activation is believed to be a protective mechanism to prevent further injuries [38]. However,
353 quadriceps AMI may persist for a long time after the original injury and can lead to
354 posttraumatic weakness and muscle atrophy [39]. Thereby it can become a limitation during
355 rehabilitation [16, 39]. Thus, it is important for clinicians to identify AMI and to devise a

356 strategy to overcome this impairment [40]. Traditional strengthening exercises have
357 demonstrated no effect on quadriceps AMI [38]. Although treatments, such as transcutaneous
358 electrical nerve stimulation (TENS) have shown to have strong effects to reduce AMI they are
359 not implemented in recommended physical interventions [38, 41]. Thus, a successful
360 identification of AMI in individuals with PFP might be an important for clinicians to be able
361 to apply an adequate treatment scheme.

362

363 **5. Limitations**

364 One limitation of this study was that pain caused by activities could not be monitored and
365 standardised. The participants performed their familiar functional activities to reproduce the
366 pain condition, which was not quantified and controlled. This study aimed to reproduce the
367 acute PFP that these individuals experience during their familiar and functional and sports
368 activities. Thus, the test procedure did not allow us to reproduce the individual familiar sport
369 environment of each participant and to monitor and standardise the painful activities.

370 It is important to note that the participants wore a pair of standard training shoes to control the
371 shoe-surface interface and to minimise the influence of footwear in the study. The standard
372 training shoes might have negatively influenced the comfort during running and thereby might
373 have influenced their biomechanical performances.

374

375 **6. Conclusions**

376 To the authors knowledge this was the first study investigating the effect of acute pain on lower
377 limb biomechanics, AMI and strength. Acute PFP pain caused a decrease of muscular activity
378 of the quadriceps and hamstrings muscles and resulted in an increase of AMI of the quadriceps.
379 However, acute pain did not alter biomechanical changes or quadriceps torque. These findings
380 show that AMI appears to be an important factor that is linked to pain in individuals with PFP,
381 which needs to be addressed appropriately in the treatment scheme.

2. References

1. Smith BE, Selfe J, Thacker D, Hendrick P, Bateman M, Moffatt F, et al. **Incidence and prevalence of patellofemoral pain: A systematic review and meta-analysis.** *PLoS One.* 2018;13: e0190892.
2. Lankhorst NE, van Middelkoop M, Crossley KM, Bierma-Zeinstra SM, Oei EH, Vicenzino B, et al. **Factors that predict a poor outcome 5-8 years after the diagnosis of patellofemoral pain: a multicentre observational analysis.** *Br J Sports Med.* 2016;50: 881-6.
3. Stathopulu E, Baildam E. **Anterior knee pain: a long-term follow-up.** *Rheumatology (Oxford).* 2003;42: 380-2.
4. Powers CM, Witvrouw E, Davis IS, Crossley KM. **Evidence-based framework for a pathomechanical model of patellofemoral pain: 2017 patellofemoral pain consensus statement from the 4th International Patellofemoral Pain Research Retreat, Manchester, UK: part 3.** *Br J Sports Med.* 2017;51: 1713-23.
5. Collins NJ, Bierma-Zeinstra SM, Crossley KM, van Linschoten RL, Vicenzino B, van Middelkoop M. **Prognostic factors for patellofemoral pain: a multicentre observational analysis.** *Br J Sports Med.* 2013;47: 227-33.
6. Rathleff MS, Rathleff CR, Olesen JL, Rasmussen S, Roos EM. **Is Knee Pain During Adolescence a Self-limiting Condition? Prognosis of Patellofemoral Pain and Other Types of Knee Pain.** *Am J Sports Med.* 2016;44: 1165-71.
7. Bazett-Jones DM. **The role of pain and muscular endurance in strength and lower extremity biomechanics in those with and without patellofemoral pain syndrome: University of Wisconsin - Milwaukee;** 2011.
8. Nakagawa TH, Serrao FV, Maciel CD, Powers CM. **Hip and knee kinematics are associated with pain and self-reported functional status in males and females with patellofemoral pain.** *Int J Sports Med.* 2013;34: 997-1002.
9. Noehren B, Sanchez Z, Cunningham T, McKeon PO. **The effect of pain on hip and knee kinematics during running in females with chronic patellofemoral pain.** *Gait Posture.* 2012;36: 596-9.
10. de Oliveira Silva D, Briani R, Pazzinatto M, Ferrari D, Aragao F, de Azevedo F. **Vertical Ground Reaction Forces are Associated with Pain and Self-Reported Functional Status in Recreational Athletes with Patellofemoral Pain.** *J Appl Biomech.* 2015;31: 409-14.
11. Seeley MK, Park J, King D, Hopkins JT. **A Novel Experimental Knee-Pain Model Affects Perceived Pain and Movement Biomechanics.** *J Athl Train.* 2013;48: 337-45.
12. Henriksen M, Alkjær T, Lund H, Simonsen EB, Graven-Nielsen T, Danneskiold-Samsøe B, et al. **Experimental quadriceps muscle pain impairs knee joint control during walking.** *J Appl Physiol.* 2007;103: 132-39.
13. Henriksen M, Alkjaer T, Simonsen EB, Bliddal H. **Experimental muscle pain during a forward lunge--the effects on knee joint dynamics and electromyographic activity.** *Br J Sports Med.* 2009;43: 503-7.
14. Henriksen M, Rosager S, Aaboe J, Graven-Nielsen T, Bliddal H. **Experimental knee pain reduces muscle strength.** *J Pain.* 2011;12: 460-7.
15. Bolgla LA, Keskula DR. **A review of the relationship among knee effusion, quadriceps inhibition, and knee function.** *J Sport Rehabil.* 2000;9: 160-68.
16. Hart JM, Pietrosimone B, Hertel J, Ingersoll CD. **Quadriceps activation following knee injuries: a systematic review.** *J Athl Train.* 2010;45: 87.
17. Rice DA, McNair PJ. **Quadriceps arthrogenic muscle inhibition: neural mechanisms and treatment perspectives.** *Semin Arthritis Rheum.* 2010;40: 250-66.

18. Crossley KM, Stefanik JJ, Selfe J, Collins NJ, Davis IS, Powers CM, et al. **2016 Patellofemoral pain consensus statement from the 4th International Patellofemoral Pain Research Retreat, Manchester. Part 1: Terminology, definitions, clinical examination, natural history, patellofemoral osteoarthritis and patient-reported outcome measures.** *Br J Sports Med.* 2016;50: 839-43.
19. Cappozzo A, Catani F, Croce UD, Leardini A. **Position and orientation in space of bones during movement: anatomical frame definition and determination.** *Clin Biomech (Bristol, Avon).* 1995;10: 171-78.
20. Hermens HJ, Freriks B, Disselhorst-Klug C, Rau G. **Development of recommendations for SEMG sensors and sensor placement procedures.** *J Electromyogr Kinesiol.* 2000;10: 361-74.
21. Callaghan MJ, Parkes MJ, Hutchinson CE, Felson DT. **Factors associated with arthrogenous muscle inhibition in patellofemoral osteoarthritis.** *Osteoarthritis Cartilage.* 2014;22: 742-6.
22. Bell AL, Pedersen DR, Brand RA. **A Comparison of the Accuracy of Several Hip Center Location Prediction Methods.** *J Biomech.* 1990;23: 617-21.
23. Perry J, Burnfield JM. **Gait Analysis: Normal and Pathological Function.** Thorofare, USA: Slack Incorporated, 2010.
24. De Luca CJ, Gilmore LD, Kuznetsov M, Roy SH. **Filtering the surface EMG signal: Movement artifact and baseline noise contamination.** *J Biomech.* 2010;43: 1573-9.
25. Heiden TL, Lloyd DG, Ackland TR. **Knee joint kinematics, kinetics and muscle co-contraction in knee osteoarthritis patient gait.** *Clin Biomech (Bristol, Avon).* 2009;24: 833-41.
26. Cohen J. **Statistical Power Analysis for the Behavioral Sciences.** Hillsdale, New Jersey: Erlbaum, 1988.
27. Farrar JT, Young JP, Jr., LaMoreaux L, Werth JL, Poole RM. **Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.** *Pain.* 2001;94: 149-58.
28. Salsich GB, Brechter JH, Powers CM. **Lower extremity kinetics during stair ambulation in patients with and without patellofemoral pain.** *Clin Biomech (Bristol, Avon).* 2001;16: 906-12.
29. Palmieri-Smith RM, McLean SG, Ashton-Miller JA, Wojtys EM. **Association of quadriceps and hamstrings cocontraction patterns with knee joint loading.** *J Athl Train.* 2009;44: 256-63.
30. Sterling M, Jull G, Wright A. **The effect of musculoskeletal pain on motor activity and control.** *J Pain.* 2001;2: 135-45.
31. Rice DA, Graven-Nielsen T, Lewis GN, McNair PJ, Dalbeth N. **The effects of experimental knee pain on lower limb corticospinal and motor cortex excitability.** *Arthritis Res Ther.* 2015;17: 204.
32. Drover JM, Forand DR, Herzog W. **Influence of active release technique on quadriceps inhibition and strength: a pilot study.** *J Manipulative Physiol Ther.* 2004;27: 408-13.
33. Graven-Nielsen T, Lund H, Arendt-Nielsen L, Danneskiold-Samsoe B, Bliddal H. **Inhibition of maximal voluntary contraction force by experimental muscle pain: a centrally mediated mechanism.** *Muscle Nerve.* 2002;26: 708-12.
34. McConnell J. **Running Injuries: The Infrapatellar Fat Pad and Plica Injuries.** *Phys Med Rehabil Clin N Am.* 2016;27: 79-89.
35. Hodges PW, Mellor R, Crossley K, Bennell K. **Pain Induced by Injection of Hypertonic Saline Into the Infrapatellar Fat Pad and Effect on Coordination of the Quadriceps Muscles.** *Arthritis Rheum.* 2009;61: 70-77.

36. Park J, Chinn DH, Squires AC, Hopkins JT. **Experimentally Induced Anterior Knee Pain Immediately Reduces Involuntary And Voluntary Quadriceps Activation.** *Med Sci Sports Exerc.* 2012;44: 943-44.
37. Selfe J, Janssen J, Callaghan M, Witvrouw E, Sutton C, Richards J, et al. **Are there three main subgroups within the patellofemoral pain population? A detailed characterisation study of 127 patients to help develop targeted intervention (TIPPs).** *Br J Sports Med.* 2016;50: 873-80.
38. Harkey MS, Gribble PA, Pietrosimone BG. **Disinhibitory interventions and voluntary quadriceps activation: a systematic review.** *J Athl Train.* 2014;49: 411-21.
39. Hopkins J, Ingersoll CD. **Arthrogenic muscle inhibition: A limiting factor in joint rehabilitation.** *J Sport Rehabil.* 2000;9: 135-59.
40. de Oliveira Silva D, Magalhaes FH, Faria NC, Ferrari D, Pazzinatto MF, Pappas E, et al. **Vastus Medialis Hoffmann Reflex Excitability Is Associated With Pain Level, Self-Reported Function, and Chronicity in Women With Patellofemoral Pain.** *Arch Phys Med Rehabil.* 2017;98: 114-19.
41. Glaviano NR, Huntsman S, Dembeck A, Hart JM, Saliba S. **Improvements in kinematics, muscle activity and pain during functional tasks in females with patellofemoral pain following a single patterned electrical stimulation treatment.** *Clin Biomech (Bristol, Avon).* 2015;32: 20-27.